Overview
HBOT for autism spectrum disorder (ASD) was a prominent topic in the mid-2000s. A small 2009 RCT (Rossignol et al.) showed benefit, but a larger follow-up trial failed to replicate the results. The current medical consensus is that HBOT for autism lacks sufficient evidence and should not be considered an established therapy. Research continues at lower-pressure protocols.
HBOT for autism attracted significant attention in the 2000s following observations that some children with ASD showed symptom improvement after HBOT courses. Theoretical rationale centred on neuroinflammation and cerebral hypoperfusion observed in some ASD imaging studies.
The Rossignol et al. 2009 RCT (BMC Pediatrics) was the key early positive trial, reporting improvements across multiple ASD symptom measures with HBOT at 1.3 ATA over 40 sessions. However, the Granpeesheh et al. 2010 follow-up — a larger and arguably better-controlled trial — failed to replicate the findings. Subsequent meta-analyses have been mixed, generally not supporting routine HBOT for ASD.
Current position of the American Academy of Pediatrics and autism medical organisations: HBOT is not an established or recommended treatment for ASD. Families considering HBOT should be aware of the mixed evidence, the typical out-of-pocket cost, and the opportunity cost of foregoing established behavioural interventions during a 40-session HBOT course.
How HBOT Works for This Condition
Hypothesised mechanisms include reduction of neuroinflammation and improvement of cerebral perfusion in regions showing hypoperfusion on imaging. Whether these mechanisms are clinically meaningful at the 1.3 ATA pressure typical of ASD trials — vs the 2.0 ATA used in Efrati-lab neurological research — remains debated.
GRADE Evidence Rating
Rossignol 2009 RCT positive at 1.3 ATA, challenged on sham design. Larger follow-up trials inconsistent.
| GRADE Domain | Assessment |
|---|---|
| Risk of bias | High |
| Consistency | Inconsistent |
| Directness | Direct |
| Precision | Imprecise |
GRADE methodology: Grading of Recommendations Assessment, Development and Evaluation. See GRADE Working Group.
Clinical Protocol
| Typical protocol | 40 sessions at 1.3–1.5 ATA (soft-shell) |
|---|---|
| Evidence level | Mixed — Not currently supported |
| FDA status | Not FDA-approved; not recommended by autism medical bodies |
Evidence Base
The initial positive signal (Rossignol 2009) did not replicate in Granpeesheh 2010. Multiple subsequent meta-analyses have not supported routine use. The American Academy of Pediatrics does not recommend HBOT for ASD.
Patient Perspective
Families considering HBOT for ASD face a difficult landscape: strong anecdotal reports of benefit alongside unreplicated trial data. Established behavioural interventions (ABA, speech therapy, OT) have substantially stronger evidence and should remain primary. HBOT, if pursued, should be considered experimental.
Cautions & Considerations
- Not an established treatment; evidence is mixed.
- Significant out-of-pocket cost without insurance coverage.
- Opportunity cost of time and money that could support behavioural interventions.
- Marketing claims often overstate the evidence.
Key Research & References
- Rossignol et al. 2009 (positive, 1.3 ATA)
- Granpeesheh et al. 2010 (negative replication)
- Multiple meta-analyses
Indexed Studies for This Condition
Linked entries in the HBOT Studies Database.
Frequently Asked Questions
Should I try HBOT for my child with autism?
The medical consensus does not currently support HBOT as an established autism treatment. Established behavioural interventions have substantially stronger evidence. Families considering HBOT should discuss with their paediatrician and understand the mixed evidence base.
Does any pressure work better for autism?
The strongest early signal was at 1.3 ATA (Rossignol 2009), but this result did not replicate. Higher pressures (2.0 ATA) have not been systematically studied in ASD.
Is HBOT safe for children?
Children generally tolerate HBOT well. The main consideration is ear equalisation; proactive myringotomy tubes may be needed in young children.
Research disclaimer: This article summarises published research for educational purposes only. Nothing here is medical advice. HBOT is a prescription medical treatment that must be administered under physician supervision in appropriately certified chambers. Discuss any treatment decisions with a qualified clinician.